HomeCompareBUFS vs CL

BUFS vs CL: Dividend Comparison 2026

BUFS yields 8.75% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CL wins by $5.1K in total portfolio value· pulled ahead in Year 9
10 years
BUFS
BUFS
● Live price
8.75%
Share price
$22.86
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$35.7K
Annual income
$1,520.26
Full BUFS calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — BUFS vs CL

📍 CL pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBUFSCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BUFS + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BUFS pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BUFS
Annual income on $10K today (after 15% tax)
$743.82/yr
After 10yr DRIP, annual income (after tax)
$1,292.22/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, CL beats the other by $3,299.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BUFS + CL for your $10,000?

BUFS: 50%CL: 50%
100% CL50/50100% BUFS
Portfolio after 10yr
$38.3K
Annual income
$3,461.11/yr
Blended yield
9.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

BUFS
No analyst data
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BUFS buys
0
CL buys
0
No recent congressional trades found for BUFS or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBUFSCL
Forward yield8.75%2.43%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$35.7K$40.8K
Annual income after 10y$1,520.26$5,401.96
Total dividends collected$12.0K$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: BUFS vs CL ($10,000, DRIP)

YearBUFS PortfolioBUFS Income/yrCL PortfolioCL Income/yrGap
1$11,575$875.08$11,012$312.01+$563.00BUFS
2$13,332$946.65$12,196$412.95+$1.1KBUFS
3$15,284$1,019.00$13,599$549.66+$1.7KBUFS
4$17,446$1,091.79$15,288$736.64+$2.2KBUFS
5$19,832$1,164.68$17,353$995.28+$2.5KBUFS
6$22,457$1,237.35$19,926$1,357.80+$2.5KBUFS
7$25,339$1,309.50$23,194$1,873.82+$2.1KBUFS
8$28,493$1,380.86$27,439$2,621.52+$1.1KBUFS
9← crossover$31,939$1,451.19$33,088$3,727.38$1.1KCL
10$35,695$1,520.26$40,806$5,401.96$5.1KCL

BUFS vs CL: Complete Analysis 2026

BUFSStock

The investment objective of the FT Vest Laddered Small Cap Moderate Buffer ETF (the "Fund") is to seek to provide investors with capital appreciation. The Fund seeks to achieve its investment objective by providing investors with small cap equity market exposure while attempting to limit downside risk through a laddered portfolio of FT Vest U.S. Small Cap Moderate Buffer ETFs (the "Underlying ETFs"). Under normal market conditions, the Fund will invest substantially all of its assets in the Underlying ETFs, which seek to provide investors with returns (before fees and expenses) that match the price return of IWM, up to a predetermined upside cap, while providing a buffer (before fees and expenses) against the first 15% of IWM losses, over a defined one-year period. The Fund intends only to acquire shares of Underlying ETFs in the secondary market and will not engage in any principal transactions with the Underlying ETFs.

Full BUFS Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this BUFS vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BUFS vs SCHDBUFS vs JEPIBUFS vs OBUFS vs KOBUFS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.